State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF vs TransMedics Group Inc — how do they compare? State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF trades at $30.77, while TransMedics Group Inc trades at $87.35 (market cap $3.10B). The key difference: State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| FLRN | TMDX | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $30.86 | $150.42 |
52-Week Low | $30.65 | $61.99 |
Market Cap | — | $3.10B |
Enterprise Value | — | $3.49B |
Signals from Pluang's Aura AI — not financial advice
FLRN trades at $30.77, showing minimal daily movement with a 0.02% gain. Technical indicators signal a bearish trend with moving averages and ADX pointing downward, though the RSI suggests potential oversold conditions. The company has maintained consistent dividend payments of $0.11 per share through mid-2026. Current financial ratios including P/E, P/S, and ROE are unavailable in the provided data, limiting fundamental assessment.
The outlook remains cautious due to bearish technical signals and limited fundamental visibility. Investment opportunity exists in the steady dividend yield, but risks include potential interest rate sensitivity as highlighted in recent financial commentary. Investors should seek updated financial statements for comprehensive analysis given the missing valuation metrics.
TransMedics Group (TMDX) trades at $86.43, down 2.24% amid recent earnings misses but maintains strong analyst support with a $99.57 consensus target. The stock shows bullish technical signals with support at $84-87, though RSI levels suggest overbought conditions. Fundamentally, the company demonstrates robust profitability with 58.69% gross margins and 22.69% net income margins, despite recent quarterly earnings falling short of expectations.
Investment outlook remains positive given strong institutional backing and growth potential in organ transplant technology, though risks include ongoing fiduciary investigations and margin pressure from increased operating costs. The stock offers 15% upside to consensus targets but requires monitoring of Q3 earnings performance and legal developments.
Trailing returns across standard periods
FLRN invests in U.S. dollar-denominated investment-grade floating rate notes with maturities under five years. It provides exposure to corporate and supranational debt whose interest payments adjust with market rates, helping to mitigate interest rate risk.
Read more on FLRN →TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →